InventisBio Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

Phase 1

Completed

Conditions: Healthy Female Volunteer

Interventions: Drug: D-0502

First Posted Date: 2022-02-07

Last Posted Date: 2022-08-08

Lead Sponsor: InventisBio Co., Ltd

Target Recruit Count: 18

Registration Number: NCT05226338

Locations: 🇺🇸
Labcorp Clinical Research Unit, Daytona Beach, Florida, United States

Study to Evaluate D-1553 in Subjects With Solid Tumors

Phase 1

Active, not recruiting

Conditions: NSCLC
CRC
Solid Tumor, Adult

Interventions: Drug: D-1553

First Posted Date: 2020-10-14

Last Posted Date: 2024-10-14

Lead Sponsor: InventisBio Co., Ltd

Target Recruit Count: 180

Registration Number: NCT04585035

Locations: 🇨🇳
Research Site, Taoyuan City, Taiwan

Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo oral tablet
Drug: D-0120

First Posted Date: 2019-09-20

Last Posted Date: 2021-02-10

Lead Sponsor: InventisBio Co., Ltd

Target Recruit Count: 40

Registration Number: NCT04097405

Locations: 🇺🇸
Syneos Health, Miami, Florida, United States

D-0120 Safety and PK/PD Study in China

Phase 1

Completed

Conditions: Hyperuricemia or Gout

Interventions: Drug: D-0120

First Posted Date: 2019-04-23

Last Posted Date: 2022-05-06

Lead Sponsor: InventisBio Co., Ltd

Target Recruit Count: 52

Registration Number: NCT03923868

Locations: 🇨🇳
Site 04, Bengbu, Anhui, China
🇨🇳
Site 03, Nanjing, Jiangsu, China
🇨🇳
Site 07, Nanjing, Jiangsu, China

and more 3 locations

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Phase 2

Completed

Conditions: Solid Tumor
NSCLC
EGFR T790M

Interventions: Drug: D-0316

First Posted Date: 2019-03-04

Last Posted Date: 2024-04-09

Lead Sponsor: InventisBio Co., Ltd

Target Recruit Count: 290

Registration Number: NCT03861156

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Food Effect Study of D-0502 Tablet in Healthy Volunteers

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: D-0502

First Posted Date: 2019-01-18

Last Posted Date: 2019-08-07

Lead Sponsor: InventisBio Co., Ltd

Target Recruit Count: 14

Registration Number: NCT03810625

Locations: 🇺🇸
Covance Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: D-0502
Drug: palbociclib

First Posted Date: 2018-03-20

Last Posted Date: 2024-01-08

Lead Sponsor: InventisBio Co., Ltd

Target Recruit Count: 200

Registration Number: NCT03471663

Locations: 🇨🇳
Local Institution, Shenyang, Liaoning, China

D-0316 First Time in Patients Ascending Dose Study

Phase 1

Completed

Conditions: Advanced Non Small Cell Lung Cancer

Interventions: Drug: D-0316

First Posted Date: 2018-03-02

Last Posted Date: 2023-04-25

Lead Sponsor: InventisBio Co., Ltd

Target Recruit Count: 84

Registration Number: NCT03452150

Locations: 🇨🇳
Research Site, Hangzhou, Zhejiang, China

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

Phase 1

Completed

Conditions: Gout

Interventions: Drug: D-0120

First Posted Date: 2017-09-25

Last Posted Date: 2018-12-19

Lead Sponsor: InventisBio Co., Ltd

Target Recruit Count: 39

Registration Number: NCT03291782

Locations: 🇺🇸
Covance Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy